Abstract
Sulbactam irreversibly inhibits the hydrolytic activity of beta-lactamases. This compound is commercially available in combination with either ampicillin or cefoperazone. In each instance, the activity of the partner antibiotic against beta-lactamase-producing bacteria is restored. One of the particular advantages of using sulbactam-containing combinations is that sulbactam itself has inherent activity against some Acinetobacter baumannii. Sulbactam combinations have not demonstrated strong selective pressures for extended-spectrum beta-lactamase-producing Enterobacteriaceae and vancomycin-resistant enterococci. In contrast to clavulanate, sulbactam does not induce class I (Ampc) chromosomal beta-lactamases in Enterobacteriaceae.
MeSH terms
-
Adult
-
Ampicillin* / administration & dosage
-
Ampicillin* / pharmacokinetics
-
Ampicillin* / therapeutic use
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / pharmacokinetics
-
Anti-Bacterial Agents / therapeutic use
-
Cefoperazone* / administration & dosage
-
Cefoperazone* / pharmacokinetics
-
Cefoperazone* / therapeutic use
-
Drug Combinations
-
Gram-Negative Bacteria / drug effects*
-
Gram-Negative Bacteria / enzymology
-
Gram-Negative Bacterial Infections / drug therapy*
-
Gram-Negative Bacterial Infections / microbiology
-
Humans
-
Microbial Sensitivity Tests
-
Sulbactam* / administration & dosage
-
Sulbactam* / pharmacokinetics
-
Sulbactam* / therapeutic use
-
beta-Lactamase Inhibitors*
Substances
-
Anti-Bacterial Agents
-
Drug Combinations
-
beta-Lactamase Inhibitors
-
Ampicillin
-
Cefoperazone
-
Sulbactam